Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII antagonists to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides and TßRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COP)), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)), particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)) associated complications.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension associated with lung disease (e.g, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)), particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)) associated complications.

Abstract: A capillary type multi-jet nozzle is provided for fabricating high throughput nanofibers by an electrospinning technique. The capillary type multi-jet nozzle includes a cap system with one or more pores and a crew system with a screw groove system. The cap system and the crew system are connected through a cap and crew system. The pores in the cap system are customized in count based on a requirement. The angle between the pores is reduced to make multiple non-interfering and non-hindering jets in less time. A TEFLON® gasket is used for proper tightening and sealing of the cap system and screw system. The cap system includes knurling at an outer surface for grip. The capillary type multi-jet nozzle is made of a conducting material to with stand a high voltage and is fabricated using micro-machining process.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

Abstract: In some aspects, the disclosure relates to ActRII-ALK4 antagonists and methods of using ActRII-ALK4 antagonists to treat, prevent, or reduce the progression rate and/or severity of heart failure (HF), particularly treating, preventing or reducing the progression rate and/or severity of one or more HF-associated comorbidities. The disclosure also provides methods of using an ActRII-ALK4 antagonist to treat, prevent, or reduce the progression rate and/or severity of heart failure associated with a variety of conditions including, but not limited to, genetic cardiomyopathies, muscle wasting diseases, and muscular dystrophies.

Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Abstract: In certain aspects, the present disclosure relates to methods of treating systemic sclerosis (SSc) using T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications of SSc, including interstitial lung disease (ILD), with T?RII antagonists of the present disclosure.

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.

Abstract: In some aspects, the disclosure relates to ActRII-ALK4 antagonists and methods of using ActRII-ALK4 antagonists to treat, prevent, or reduce the progression rate and/or severity of heart failure (HF), particularly treating, preventing or reducing the progression rate and/or severity of one or more HF-associated comorbidities. The disclosure also provides methods of using an ActRII-ALK4 antagonist to treat, prevent, or reduce the progression rate and/or severity of heart failure associated with a variety of conditions including, but not limited to, heart failure associated with aging.

Abstract: Solutions for enabling lower privilege users (e.g., applications, virtualized computing environment applications such as virtual machines or containers) to perform requests for service (e.g., remote procedure calls) that require higher privilege include: receiving, by a relay service executing at a first privilege level, from an application executing at a lower privilege level, a received request for service. The first privilege level is sufficient for the request, however, the application's privilege level is insufficient. The relay service determines whether the application is authorized to perform the request by comparing the application identity and the request with privilege exception information (e.g., a list of application identities and corresponding requests that are subject to privilege exception). If the application's request is authorized, the relay service relays the request (e.g.

Abstract: In certain aspects, the disclosure provides compositions and methods for treating spinal muscular atrophy. For example, in some embodiments, the disclosure provides ALK4:ActRIIB antagonists that may be used to treat spinal muscular atrophy, particularly treating one or more complications of spinal muscular atrophy including, for example, increasing muscle mass muscle strength, and bone mineral density.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising variant ActRIIB polypeptides or heteromultimers thereof to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: An extrusion system (100) according to certain aspects includes at least one infrared emitting device (102) arranged in a generally cylindrical shape with a hollow interior. The at least one infrared emitting device (102) is positioned downstream of an outlet of an extrusion die (110) to irradiate a perimeter of wet extrudate material in a uniform manner to form stiffened wet extrudate material (116) before such material is received by an extrudate support channel (118). The at least one infrared emitting device (102) generally uniformly stiffens the skin of the wet extrudate material (116) to resist mechanical deformation of the extrudate material during subsequent handling steps. Such skin stiffening allows for increased tolerance of handling forces and permits extrusion of softer wet extrudate material without compromising the shape of a fired ceramic product.

Abstract: An extrusion system (100) includes at least one sensor (102, 104) to detect localized presence of oil (701) on an exterior surface (715) or skin of wet extrudate material (714 e.g., ceramic material having a honeycomb cross-sectional shape), and at least one infrared emitting device (106, 108) configured to impinge infrared emissions on at least a portion of the exterior surface responsive to one or more sensor signals. Localized impingement of infrared emissions may reduce presence of oil streaks (701) without undue differential drying of the extrudate skin (715), and avoid surface fissures that would otherwise result in fired ceramic bodies. Separately controllable infrared emitters (502), or at least one controllable infrared blocking or redirecting element (603), may be used to impinge infrared emissions on selected areas. A humidification section (120) arranged downstream of infrared emitters (106, 108) may be used to at least partially rehydrate the wet extrudate material, if necessary.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of hyperglycemia, particularly treating, preventing or reducing the progression rate and/or severity of one or more hyperglycemia-associated complications.

Abstract: Methods and systems for managing unlocking of an electronic device are provided. A method includes receiving an unlocking input from a user, authenticating the unlocking input, generating a first pre-wakeup command of initializing a progress action for the electronic device, generating a second pre-wakeup command of whether to complete the progress action or to retrogress the progress action based on the authenticating of the unlocking input, and determining whether to unlock the electronic device based on the second pre-wakeup command.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.

Abstract: The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.